

(b) The antiviral fluorochrome-conjugated antibodies to be used shall depend on the type of cells required to be tested for extraneous viruses as specified in an applicable Standard Requirement or in a filed Outline of Production. Antiviral fluorochrome-conjugated antibodies specific for the extraneous viruses shall be applied to each respective type of cell in accordance with the following list. Under certain circumstances, additional tests may need to be conducted, as determined by the Administrator. When a specific antiviral fluorochrome-conjugated antibody is used in testing for the listed extraneous viruses specified in more than one cell type, it need only be applied to the most susceptible cell type.

- (1) All cells shall be tested for:
 - (i) Bovine virus diarrhea virus;
 - (ii) Reovirus; and
 - (iii) Rabies virus.
- (2) Bovine, caprine, and ovine cells shall, in addition, be tested for:
 - (i) Bluetongue virus;
 - (ii) Bovine adenoviruses;
 - (iii) Bovine parvovirus; and
 - (iv) Bovine respiratory syncytial virus.
- (3) Canine cells shall, in addition, be tested for:
 - (i) Canine coronavirus;
 - (ii) Canine distemper virus; and
 - (iii) Canine parvovirus.
- (4) Equine cells shall, in addition, be tested for:
 - (i) Equine herpesvirus; and
 - (ii) Equine viral arteritis virus.
- (5) Feline cells shall, in addition, be tested for:
 - (i) Feline infectious peritonitis virus; and
 - (ii) Feline panleukopenia virus.
- (6) Porcine cells shall, in addition, be tested for:
 - (i) Porcine adenovirus;
 - (ii) Porcine parvovirus;
 - (iii) transmissible gastroenteritis virus; and
 - (iv) Porcine hemagglutinating encephalitis virus.
- (7) Firms that do not have rabies virus on premises either for research or production purposes are exempt from having to produce positive rabies virus control monolayers. Fixed positive rabies virus control monolayers will be

provided by the National Veterinary Services Laboratories.

(c) After staining, each group of monolayers shall be examined for the presence of specific fluorescence attributable to the presence of extraneous viruses.

(1) If the material under test shows any evidence of specific viral fluorescence, it is unsatisfactory and may not be used; *Provided*, That, if specific fluorescence attributable to the virus being tested for is absent in the positive control monolayers, the test is inconclusive and may be repeated.

(2) If the fluorescence of the monolayers inoculated with the specific virus as positive controls is equivocal, or if the negative monolayers show equivocal fluorescence indicating possible viral contamination, or both, the test shall be declared inconclusive, and may be repeated; *Provided*, That, if the test is not repeated, the material under test shall be regarded as unsatisfactory for use in the production of biologics.

[60 FR 24548, May 9, 1995]

INGREDIENT REQUIREMENTS

§ 113.50 Ingredients of biological products.

All ingredients used in a licensed biological product shall meet accepted standards of purity and quality; shall be sufficiently nontoxic so that the amount present in the recommended dose of the product shall not be toxic to the recipient; and in the combinations used shall not denature the specific substances in the product below the minimum acceptable potency within the dating period when stored at the recommended temperature.

[38 FR 29889, Oct. 30, 1973]

§ 113.51 Requirements for primary cells used for production of biologics.

Primary cells used to prepare biological products shall be derived from normal tissue of healthy animals. When prescribed in an applicable Standard Requirement or in the filed Outline of Production, each batch of